The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
The powerful world of antisense oligonucleotides: From bench to bedside
Open accessAbstract
Antisense oligonucleotides (ASOs) represent a new and highly promising class of drugs for personalized medicine. In the last decade, major chemical developments and improvements of the backbone structure of ASOs have transformed them into true approved and commercialized drugs. ASOs target both DNA and RNA, including pre‐mRNA, mRNA, and ncRDA, based on sequence complementary. They are designed to be specific for each identified molecular and genetic alteration to restore a normal, physiological situation. Thus, the characterization of the underpinning mechanisms and alterations that sustain pathology is critical for accurate ASO‐design. ASOs can be used to cure both rare and common diseases, such as orphan genetic alterations and cancer. Through pioneering examples, this review shows the versatility of the mechanisms of action that provide ASOs with the potential capacity to achieve custom treatment, revolutionizing personalized medicine. This article is categorized under: RNA in Disease and Development > RNA in Disease RNA Interactions with Proteins and Other Molecules > Small Molecule–RNA Interactions
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhang, X., Wang, S., Wang, H., Cao, J., Huang, X., Chen, Z., Xu, P., Sun, G., Xu, J., Lv, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0935-5 · Cited by 842
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“…kinases, such as specific inhibitors of the constitutively active form of the BRAF kinase (BRAF-V600) in BRAF-V600 mutated metastatic melanoma (Chapman et al., 2011) The use of blocking antibodies specific for an oncogenic pathway has also resulted in therapeutic success (antiEGFR antibody in…”
BackgroundThe HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · cited 1×
“These non-coding RNAs are, therefore, prime targets for ASOs (Huarte, 2015; Ling, Fabbri, & Calin, 2013; Rupaimoole & Slack, 2017).”
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Brook, J. D., McCurrach, M. E., Harley, H. G., Buckler, A. J., Church, D., Aburatani, H., Hunter, K., Stanton, V. P., Thirion, J.-P., Hudson, T., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90154-5 · Cited by 2,777
The emerging role of lncRNAs in cancer
Huarte, M. (2015) · Nature Medicine · doi:10.1038/nm.3981 · Cited by 2,702
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules
Egholm, M., Buchardt, O., Christensen, L., Behrens, C., Freier, S. M., Driver, D. A., Berg, R. H., Kim, S. K., Norden, B., & Nielsen, P. E. (1993) · Nature · doi:10.1038/365566a0 · Cited by 2,079
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Prevalence of Muscular Dystrophies: A Systematic Literature Review
Theadom, A., Rodrigues, M., Roxburgh, R., Balalla, S., Higgins, C., Bhattacharjee, R., Jones, K., Krishnamurthi, R., & Feigin, V. (2014) · Neuroepidemiology · doi:10.1159/000369343 · Cited by 2,046
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Crystal Structure of Argonaute and Its Implications for RISC Slicer Activity
Song, J.-J., Smith, S. K., Hannon, G. J., & Joshua-Tor, L. (2004) · Science · doi:10.1126/science.1102514 · Cited by 1,470
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
Gutschner, T., Hämmerle, M., Eißmann, M., Hsu, J., Kim, Y., Hung, G., Revenko, A., Arun, G., Stentrup, M., Groß, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2850 · Cited by 1,415
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Dystrophin and mutations: one gene, several proteins, multiple phenotypes
Muntoni, F., Torelli, S., & Ferlini, A. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00585-4 · Cited by 1,124
Napoli, C., Lemieux, C., & Jorgensen, R. (1990) · The Plant Cell · doi:10.2307/3869076 · Cited by 1,101
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094
Trinucleotide repeat length instability and age of onset in Huntington's disease
Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., Ross, C., Franz, M., Abbott, M., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-387 · Cited by 1,089
A day in the life of the spliceosome
Matera, A. G., & Wang, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3742 · Cited by 1,074
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Antisense technologies: Improvement through novel chemical modifications
Kurreck, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03555.x · Cited by 1,006
Revealing the world of RNA interference
Mello, C. C., & Conte, D. (2004) · Nature · doi:10.1038/nature02872 · Cited by 997
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 827
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 778
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P., & Lee, S.-S. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.005 · Cited by 731
Angelman syndrome: a review of the clinical and genetic aspects
Clayton-Smith, J., & Laan, L. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.2.87 · Cited by 687
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684 · cited 1×
“The modified cells are then injected back into the patient (Cavazzana-Calvo et al., 2010; Thompson et al., 2018).”
BackgroundAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Rosenberg, J. E., O’Donnell, P. H., Balar, A. V., McGregor, B. A., Heath, E. I., Yu, E. Y., Galsky, M. D., Hahn, N. M., Gartner, E. M., Pinelli, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01140 · Cited by 642
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Physicochemical properties of phospborothioate oligodeoxynucleotides
Stein, C. A., Subasinghe, C., Shinozuka, K., & Cohen, J. S. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.8.3209 · Cited by 591
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss
Arun, G., Diermeier, S., Akerman, M., Chang, K.-C., Wilkinson, J. E., Hearn, S., Kim, Y., MacLeod, A. R., Krainer, A. R., Norton, L., et al. (2016) · Genes & Development · doi:10.1101/gad.270959.115 · Cited by 585
Melanoma addiction to the long non-coding RNA SAMMSON
Leucci, E., Vendramin, R., Spinazzi, M., Laurette, P., Fiers, M., Wouters, J., Radaelli, E., Eyckerman, S., Leonelli, C., Vanderheyden, K., et al. (2016) · Nature · doi:10.1038/nature17161 · Cited by 582
Inhibition of microRNA function by antimiR oligonucleotides
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012) · Silence · doi:10.1186/1758-907x-3-1 · Cited by 560
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA
Meng, L., Ward, A. J., Chun, S., Bennett, C. F., Beaudet, A. L., & Rigo, F. (2015) · Nature · doi:10.1038/nature13975 · Cited by 518
Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 518
Tabulation of human transthyretin (TTR) variants, 2003
Connors, L. H., Lim, A., Prokaeva, T., Roskens, V. A., & Costello, C. E. (2003) · Amyloid · doi:10.3109/13506120308998998 · Cited by 505
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
Wheeler, T. M., Leger, A. J., Pandey, S. K., MacLeod, A. R., Nakamori, M., Cheng, S. H., Wentworth, B. M., Bennett, C. F., & Thornton, C. A. (2012) · Nature · doi:10.1038/nature11362 · Cited by 502
A Genetic Screen for Candidate Tumor Suppressors Identifies REST
Westbrook, T. F., Martin, E. S., Schlabach, M. R., Leng, Y., Liang, A. C., Feng, B., Zhao, J. J., Roberts, T. M., Mandel, G., Hannon, G. J., et al. (2005) · Cell · doi:10.1016/j.cell.2005.03.033 · Cited by 489
Formation and Repair of Interstrand Cross-Links in DNA
Noll, D. M., Mason, T. M., & Miller, P. S. (2006) · Chemical Reviews · doi:10.1021/cr040478b · Cited by 484
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Executive and mnemonic functions in early Huntington's disease
Lawrence, A. D., Sahakian, B. J., Hodges, J. R., Rosser, A. E., Lange, K. W., & Robbins, T. W. (1996) · Brain · doi:10.1093/brain/119.5.1633 · Cited by 386
Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides
Inoue, H., Hayase, Y., Imura, A., Iwai, S., Miura, K., & Ohtsuka, E. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.15.6131 · Cited by 362
DNA-based digital tension probes reveal integrin forces during early cell adhesion
Zhang, Y., Ge, C., Zhu, C., & Salaita, K. (2014) · Nature Communications · doi:10.1038/ncomms6167 · Cited by 354
Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy
Brooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R., Florence, J., King, W. M., Pandya, S., Robison, J., Schierbecker, J., et al. (1989) · Neurology · doi:10.1212/wnl.39.4.475 · Cited by 353
Shen, W., De Hoyos, C. L., Migawa, M. T., Vickers, T. A., Sun, H., Low, A., Bell, T. A., Rahdar, M., Mukhopadhyay, S., Hart, C. E., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0106-2 · Cited by 345
Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S. E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T., et al. (2015) · Nature Medicine · doi:10.1038/nm.3765 · Cited by 327
Flanigan, K. M., Dunn, D. M., von Niederhausern, A., Soltanzadeh, P., Gappmaier, E., Howard, M. T., Sampson, J. B., Mendell, J. R., Wall, C., King, W. M., et al. (2009) · Human Mutation · doi:10.1002/humu.21114 · Cited by 321
Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells
van Deutekom, J. C. T. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.15.1547 · Cited by 293
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Huang, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.003 · Cited by 291
Ambrose, C. M., Duyao, M. P., Barnes, G., Bates, G. P., Lin, C. S., Srinidhi, J., Baxendale, S., Hummerich, H., Lehrach, H., Altherr, M., et al. (1994) · Somatic Cell and Molecular Genetics · doi:10.1007/bf02257483 · Cited by 278
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
Noncoding RNAs in cancer therapy resistance and targeted drug development
Wang, W.-T., Han, C., Sun, Y.-M., Chen, T.-Q., & Chen, Y.-Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0748-z · Cited by 265
Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes
Mabb, A. M., Judson, M. C., Zylka, M. J., & Philpot, B. D. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.04.001 · Cited by 263
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy
Mulders, S. A. M., van den Broek, W. J. A. A., Wheeler, T. M., Croes, H. J. E., van Kuik-Romeijn, P., de Kimpe, S. J., Furling, D., Platenburg, G. J., Gourdon, G., Thornton, C. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905780106 · Cited by 257
A microRNA switch regulates the rise in hypothalamic GnRH production before puberty
Messina, A., Langlet, F., Chachlaki, K., Roa, J., Rasika, S., Jouy, N., Gallet, S., Gaytan, F., Parkash, J., Tena-Sempere, M., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4298 · Cited by 255
Reilley, M. J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 245
Perry, C. M., & Barman Balfour, J. A. (1999) · Drugs · doi:10.2165/00003495-199957030-00010 · Cited by 243
Locked nucleic acid: modality, diversity, and drug discovery
Hagedorn, P. H., Persson, R., Funder, E. D., Albæk, N., Diemer, S. L., Hansen, D. J., Møller, M. R., Papargyri, N., Christiansen, H., Hansen, B. R., et al. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.018 · Cited by 238
Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications
Benizri, S., Gissot, A., Martin, A., Vialet, B., Grinstaff, M. W., & Barthélémy, P. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00761 · Cited by 231
Campbell, J. M., Bacon, T. A., & Wickstrom, E. (1990) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(90)90084-p · Cited by 230
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01327-2 · Cited by 222
Liang, X.-H., Shen, W., Sun, H., Migawa, M. T., Vickers, T. A., & Crooke, S. T. (2016) · Nature Biotechnology · doi:10.1038/nbt.3589 · Cited by 212
Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense
Aartsma-Rus, A., Janson, A. A. M., Kaman, W. E., Bremmer-Bout, M., van Ommen, G.-J. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2004) · The American Journal of Human Genetics · doi:10.1086/381039 · Cited by 200
The role of peroxiredoxins in cancer
Nicolussi, A., D'Inzeo, S., Capalbo, C., Giannini, G., & Coppa, A. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1129 · Cited by 200
Santos, R. D., Raal, F. J., Catapano, A. L., Witztum, J. L., Steinhagen-Thiessen, E., & Tsimikas, S. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304549 · Cited by 196
Inotersen: First Global Approval
Keam, S. J. (2018) · Drugs · doi:10.1007/s40265-018-0968-5 · Cited by 188
Epidemiology and natural history of hepatitis C virus infection.
Lee, M., Yang, H., Yuan, Y., L'Italien, G. J., & Chen, C. (2014) · PubMed · doi:10.3748/wjg.v20.i28.9270 · Cited by 186
Orengo, J. P., Chambon, P., Metzger, D., Mosier, D. R., Snipes, G. J., & Cooper, T. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708519105 · Cited by 178
Furdon, P. J., Dominski, Z., & Kole, R. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.22.9193 · Cited by 176
Gupta, N., Fisker, N., Asselin, M.-C., Lindholm, M., Rosenbohm, C., Ørum, H., Elmén, J., Seidah, N. G., & Straarup, E. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010682 · Cited by 174
Tanowitz, M., Hettrick, L. A., Revenko, A. S., Kinberger, G. A., Prakash, T. P., & Seth, P. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx960 · Cited by 165
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
AMANTANA, A., & IVERSEN, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.07.001 · Cited by 163
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Prakash, T. P., Mullick, A. E., Lee, R. G., Yu, J., Yeh, S. T., Low, A., Chappell, A. E., Østergaard, M. E., Murray, S., Gaus, H. J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz354 · Cited by 162
Fomivirsen: Clinical Pharmacology and Potential Drug Interactions
Geary, R. S., Henry, S. P., & Grillone, L. R. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00002 · Cited by 160
Mipomersen Sodium: First Global Approval
Hair, P., Cameron, F., & McKeage, K. (2013) · Drugs · doi:10.1007/s40265-013-0042-2 · Cited by 160
van der Ree, M. H., van der Meer, A. J., van Nuenen, A. C., de Bruijne, J., Ottosen, S., Janssen, H. L., Kootstra, N. A., & Reesink, H. W. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13432 · Cited by 159
Progression of transthyretin amyloid neuropathy after liver transplantation
Liepnieks, J. J., Zhang, L. Q., & Benson, M. D. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea15d4 · Cited by 158
Liang, X., Sun, H., Shen, W., Wang, S., Yao, J., Migawa, M. T., Bui, H., Damle, S. S., Riney, S., Graham, M. J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx632 · Cited by 158
No‐go decay: a quality control mechanism for RNA in translation
Harigaya, Y., & Parker, R. (2010) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.17 · Cited by 143
Fomivirsen approved for CMV retinitis.
Roehr, B. (1998) · PubMed · Cited by 140
The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy
Bushby, K. M. D., Gardner‐Medwin, D., Nicholson, L. V. B., Johnson, M. A., Haggerty, I. D., Cleghorn, N., Harris, J. B., & Bhattacharyal, S. S. (1993) · Journal of Neurology · doi:10.1007/bf00858726 · Cited by 132
Mansoor, M., & Melendez, A. J. (2008) · Gene Regulation and Systems Biology · doi:10.4137/grsb.s418 · Cited by 130
Crooke, S. T., Baker, B. F., Xia, S., Yu, R. Z., Viney, N. J., Wang, Y., Tsimikas, S., & Geary, R. S. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0753 · Cited by 127
Targeted therapies: how personal should we go?
Martini, M., Vecchione, L., Siena, S., Tejpar, S., & Bardelli, A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.164 · Cited by 124
Shimojo, M., Paquette, A. J., Anderson, D. J., & Hersh, L. B. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.6788 · Cited by 124
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
Akdim, F., Tribble, D. L., Flaim, J., Yu, R. Z., Su, J. Q., Geary, R. S., Baker, B. F., Fuhr, R., Wedel, M. K., & Kastelein, J. J. P. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr148 · Cited by 123
Locked nucleic acid as a novel class of therapeutic agents
Veedu, R. N., & Wengel, J. (2009) · RNA Biology · doi:10.4161/rna.6.3.8807 · Cited by 123
A non-coding function of TYRP1 mRNA promotes melanoma growth
Gilot, D., Migault, M., Bachelot, L., Journé, F., Rogiers, A., Donnou‐Fournet, E., Mogha, A., Mouchet, N., Pinel‐Marie, M., Mari, B. P., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3623 · Cited by 107
Self-citationHammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts
Langlois, M., Lee, N. S., Rossi, J. J., & Puymirat, J. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00068-6 · Cited by 104
Steffens, R., & Leumann, C. J. (1997) · Journal of the American Chemical Society · doi:10.1021/ja972597x · Cited by 103
Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R., & Nicklin, P. L. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00190-1 · Cited by 103
Chi, K. N., Higano, C. S., Blumenstein, B. A., Ferrero, J.-M., Reeves, J. A., Feyerabend, S., Gravis, G., Merseburger, A. S., Stenzl, A., Bergman, A. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30168-7 · Cited by 98
Ribonuclease H (Hybrid) in Escherichia coli
Miller, H. I., Riggs, A. D., & Gill, G. N. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44152-5 · Cited by 91
Duchenne muscular dystrophy: current cell therapies
Sienkiewicz, D., Kułąk, W., Okurowska-Zawada, B., Paszko-Patej, G., & Kawnik, K. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615586123 · Cited by 89
Jearawiriyapaisarn, N., Moulton, H. M., Sazani, P., et al. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp335 · Cited by 85
Antisense molecules: A new class of drugs
Potaczek, D. P., Garn, H., Unger, S. D., & Renz, H. E. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1344 · Cited by 81
Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
Kim, Y., Jo, M., Schmidt, J., Luo, X., Prakash, T. P., Zhou, T., Klein, S., Xiao, X., Post, N. M., Yin, Z., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.06.009 · Cited by 81
Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.
McCall, A. L., & Farhy, L. S. (2013) · PubMed · Cited by 80
Lentiviral vectors can be used for full-length dystrophin gene therapy
Counsell, J. R., Asgarian, Z., Meng, J., Ferrer, V., Vink, C. A., Howe, S. J., Waddington, S. N., Thrasher, A. J., Muntoni, F., Morgan, J. E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00152-5 · Cited by 75
Mechanism of action of DNA topoisomerase inhibitors
Binaschi, M., Zunino, F., & Capranico, G. (1995) · Stem Cells · doi:10.1002/stem.5530130408 · Cited by 70
Lian, Y., Huang, Y.-L., Wang, J.-L., Deng, M.-H., Xia, T., Zeng, M., Chen, M., Wang, H., & Huang, Y. (2018) · Aging · doi:10.18632/aging.101510 · Cited by 69
Drugging the RNA WorldPreprint
Disney, M. D., Dwyer, B. G., & Childs‐Disney, J. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034769 · Cited by 68
Dřevínek, P., Pressler, T., Cipolli, M., Boeck, K. D., Schwarz, C., Bouisset, F., Boff, M., Henig, N. R., Paquette-Lamontagne, N., Montgomery, S., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.014 · Cited by 67
Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias
Kantarjian, H. M., & Talpaz, M. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90098-3 · Cited by 66
mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
Liang, X., Nichols, J. G., Hsu, C., Vickers, T. A., & Crooke, S. T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz500 · Cited by 62
Odate, S., Veschi, V., Yan, S., Lam, N., Woessner, R. D., & Thiele, C. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1317 · Cited by 61
Ricotta, D. N., & Frishman, W. H. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e31823424be · Cited by 60
Huang, L., Low, A., Damle, S. S., Keenan, M. M., Kuntz, S., Murray, S., Monia, B. P., & Guo, S. (2018) · Genome biology · doi:10.1186/s13059-017-1386-9 · Cited by 60
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
Sermet‐Gaudelus, I., Clancy, J. P., Nichols, D. P., Nick, J. A., Boeck, K. D., Solomon, G. M., Mall, M. A., Bolognese, J. A., Bouisset, F., den Hollander, W., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.10.015 · Cited by 57
The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer
Takakura, K., Kawamura, A., Torisu, Y., Koido, S., Yahagi, N., & Saruta, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133331 · Cited by 54
Targeted therapy in severe asthma today: focus on immunoglobulin E
Pelaia, G., Canonica, G. W., Matucci, A., Paolini, R., Triggiani, M., & Paggiaro, P. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s130743 · Cited by 50
A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
Shimojo, M., Kasahara, Y., Inoue, M., Tsunoda, S., Shudo, Y., Kurata, T., & Obika, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43100-1 · Cited by 47
Rabinovitz, S., Kaufman, Y., Ludwig, G., Razin, A., & Shemer, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116661109 · Cited by 43
Single-molecule study of the CUG repeat–MBNL1 interaction and its inhibition by small molecules
Jahromi, A. H., Honda, M., Zimmerman, S. C., & Spies, M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt330 · Cited by 35
Liu, F.-W., Shimakami, T., Murai, K., Shirasaki, T., Funaki, M., Honda, M., Murakami, S., Yi, M., Tang, H., & Kaneko, S. (2016) · Scientific Reports · doi:10.1038/srep30939 · Cited by 27
Definition and identification of small RNA sponges: Focus on miRNA sequestration.
Migault, M., Donnou-Fournet, E., Galibert, M., & Gilot, D. (2017) · Methods · doi:10.1016/j.ymeth.2016.11.012 · Cited by 24
Self-citationBlain, A. M., Greally, E., McClorey, G., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198897 · Cited by 24
Gold Therapy in Rheumatoid Arthritis
BROWNING, J. S., Rice, R. M., Lee, W. V., & Baker, L. M. (1947) · New England Journal of Medicine · doi:10.1056/nejm194709182371202 · Cited by 18
Li, D., Fu, Q., Li, M., Li, J., Yin, C., Zhao, J. H., & Li, F. (2017) · Future Oncology · doi:10.2217/fon-2016-0468 · Cited by 15
Rearrangement of the human ABL oncogene in a glioblastoma.
Heisterkamp, N., Morris, C. M., Sender, L., Knoppel, E., Uribe, L., Cui, M. Y., & Groffen, J. (1990) · PubMed · Cited by 11
Cited by
Recent advances in exosome-mediated nucleic acid delivery for cancer therapy
Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01472-z · Cited by 306
Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A., & Collaborative, N. =. 1. (2024) · Communications Medicine · doi:10.1038/s43856-023-00419-1 · Cited by 273
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169
Pires, M., & Rego, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010778 · Cited by 157
Metadata
- Authors
- Quemener, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M.
- Venue
- WIREs RNA
- Publisher
- Wiley
- Published
- 2020-03-31
- Volume
- 11
- Issue
- 5
- Pages
- e1594-e1594
- ISSN
- 1757-7004 (ISSN-L)
- 1757-7012
- OpenAlex
- W3013945467
- Cited by
- 280
- References
- 150
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.